

ACComplishments During ACCRF's First 9 Years

	2005	2014
Research Network	Few investigators, modest interest in ACC	More than 30 investigators globally with strong interest in ACC
Biobanking	Limited	Repositories with hundreds of frozen tumor specimens
Cell Lines	Multiple invalid models	Misidentifications discovered; valid models in development
Animal Models	None	20 mouse xenografts developed; progress in transgenic models
Genomics	Sporadic reports of translocations	<ul style="list-style-type: none"> • Discovery of recurrent t(6;9) and MYB-NFIB fusion gene • Identification of potential molecular targets with therapies: FGFR, IGF-1R, HDAC, NOTCH, TRK
Preclinical Drug Screens	None in valid models	<ul style="list-style-type: none"> • Open xenograft platform for academia and industry • Strong relationships with biopharmaceutical companies • 30 approved and 40 novel compounds screened in xenografts
Mobilizing Patients	Limited	Tissue donations, clinical trial accrual and over \$10 million in donations
NIH Commitments	Negligible	Over \$20 million for salivary gland tumor research (NIDCR)
Clinical Trials	Few, small & haphazard	Multiple science-driven trials with improved designs, enrollment, data quality and patient outcomes